<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856764</url>
  </required_header>
  <id_info>
    <org_study_id>ROF-DERM_203</org_study_id>
    <secondary_id>2012-003000-12</secondary_id>
    <secondary_id>U1111-1133-6455</secondary_id>
    <nct_id>NCT01856764</nct_id>
  </id_info>
  <brief_title>Topical Roflumilast in Adults With Atopic Dermatitis</brief_title>
  <official_title>A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation - on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of topical roflumilast on the reduction
      of atopic dermatitis lesions in adults with atopic dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 15 in Participants' Assessment of Pruritus</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>0.5% Roflumilast Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Roflumilast Cream</intervention_name>
    <description>Roflumilast 0.5% cream</description>
    <arm_group_label>0.5% Roflumilast Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Roflumilast formulation vehicle</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is male or female between 18 to 65 years of age, inclusive, with atopic dermatitis
             (AD) meeting Hanifin and Rajka's criteria.

          2. Has lesional skin areas of moderate severity characterized by modified local SCORing
             Atopic Dermatitis (SCORAD) of at least 4, with an erythema score ≥2, and confirmed by
             a qualified investigator.

          3. Has an index/target lesion of moderate severity approximately 20 cm^2, suitable for
             topical treatment.

          4. Is willing to wash out from AD current active therapy prior to entry in the study.

          5. Is willing and able to apply the study medication as directed, comply with study
             instructions and commit to all follow-up visits for the duration of the study.

          6. If a male who is nonsterilized and sexually active with a female partner of
             childbearing potential, agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          7. If a female of childbearing potential who is sexually active with a nonsterilized male
             partner, agrees to use routinely adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          8. Is capable of understanding and complying with protocol requirements in the opinion of
             the investigator.

          9. Signs and dates a written informed consent form and any required privacy authorization
             prior to the initiation of any study procedures.

        Exclusion Criteria:

          1. Has received any investigational compound within 30 days, or within 5 half-lives of
             the compound (whichever is longer) prior to the Screening visit.

          2. Has a history of AD unresponsive or poorly responsive to topical treatments.

          3. Has a history of hypersensitivity to phosphodiesterase (PDE)-4 inhibitors or to drugs
             of similar chemical classes or any inactive ingredients of the trial medication.

          4. Has clinically significant abnormal hematological parameters of hemoglobin, hematocrit
             or erythrocytes at Screening, in the judgment of the investigator.

          5. Has a history or current clinically relevant allergy or idiosyncrasy to drugs or food.

          6. Had extensive exposure to ultraviolet (UV) light in the 4 weeks prior to first
             application of study medication, including tanning and sun beds or is intending to
             have such exposure during the study treatment that may interfere with the study
             assessments as judged by the investigator.

          7. Has evidence of oozing of target lesion.

          8. Has a current skin complication such as erythroderma or overt bacterial or viral
             infection for which treatment with anti-infectives are indicated.

          9. Had systemic treatment with corticosteroids or retinoids for studied condition within
             3 months prior to the first application of study medication.

         10. Had topical or transdermal treatments, such as but not limited to retinoids, nicotine
             or hormone replacement therapies, on or near the intended site of application within 4
             weeks prior to first application of study medication.

         11. Had treatment with systemic/locally acting medications/procedures that might counter
             or influence the study aim within 4 weeks prior to first application of study
             medication and during the study (e.g., anti-histamines).

         12. Has used emollients/moisturizers on areas to be treated within 24 hours prior to the
             first application of study medication.

         13. Has used biologics at any time for treatment of AD.

         14. Is currently enrolled in an investigational drug or device study.

         15. Has any clinically significant illness that may influence the outcome of the trial
             from 4 weeks before Day 1 through trial completion.

         16. Has alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) values
             greater than 2.0 × upper limit of normal (ULN), or other clinically significant
             abnormal laboratory test that, in the opinion of the Investigator, would compromise
             the participant's ability to safely complete the trial.

         17. Has a significant medical condition and/or conditions that, in the opinion of the
             Investigator, would interfere with the treatment, safety or compliance with the
             protocol.

         18. Has a history of infection with hepatitis B, hepatitis C, or human immunodeficiency
             virus.

         19. Has a history of alcoholism or illicit drug abuse within 5 years prior to the
             Screening Visit or is currently consuming &gt;14 alcoholic drinks per week.

         20. If female, is pregnant, nursing or planning a pregnancy during the study period.

         21. Has a history of cancer that has not been in remission for at least 5 years prior to
             the first dose of study medication. This criterion does not apply to those
             participants with successfully resected basal cell or stage I squamous cell carcinoma
             of the skin.

         22. Has a chronic or clinically relevant acute infection.

         23. Has a history of depression associated with suicidal ideation and behavior.

         24. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.

         25. Is an immediate family member, a study site employee, in a dependent relationship with
             a study site employee who is involved in conduct of this study (e.g., spouse, parent,
             child, sibling) or at risk for consenting under duress.

         26. Was institutionalized because of a legal or regulatory order.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gera</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>South Africa</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>March 11, 2015</results_first_submitted>
  <results_first_submitted_qc>June 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2015</results_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atopic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 3 centers in Germany from 10 June 2013 to 18 March 2014.</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of Atopic Dermatitis were enrolled in 1 of 2 twice daily (BID) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.5% Roflumilast Cream</title>
          <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Cream</title>
          <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>0.5% Roflumilast Cream</title>
          <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Cream</title>
          <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" spread="11.50"/>
                    <measurement group_id="B2" value="36.5" spread="9.65"/>
                    <measurement group_id="B3" value="34.6" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.3" spread="9.27"/>
                    <measurement group_id="B2" value="174.9" spread="10.13"/>
                    <measurement group_id="B3" value="176.1" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.72" spread="21.757"/>
                    <measurement group_id="B2" value="78.31" spread="12.965"/>
                    <measurement group_id="B3" value="80.02" spread="17.762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.65" spread="5.007"/>
                    <measurement group_id="B2" value="25.59" spread="3.477"/>
                    <measurement group_id="B3" value="25.62" spread="4.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classificaiton</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Reproductive Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically sterile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female of childbearing potential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N/A (male participant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Modified Local SCORing Atopic Dermatitis (SCORAD)</title>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.60" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="B2" value="5.85" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="B3" value="5.725" lower_limit="4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Transepidermal Water Loss (TEWL) Mean</title>
          <units>g/m^2/hr</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.47" lower_limit="17.8" upper_limit="69.8"/>
                    <measurement group_id="B2" value="41.57" lower_limit="17.8" upper_limit="63.3"/>
                    <measurement group_id="B3" value="41.52" lower_limit="17.8" upper_limit="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Participant Assessment of Pruritis</title>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.05" lower_limit="0.0" upper_limit="9.0"/>
                    <measurement group_id="B2" value="5.00" lower_limit="2.0" upper_limit="10.0"/>
                    <measurement group_id="B3" value="5.025" lower_limit="0.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)</title>
        <description>Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>All randomized participants who received at least one application of any double-blind study medication with a score at Day 15. One subject in the 0.5% Roflumilast group was missing Day 15 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5% Roflumilast Cream</title>
            <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD)</title>
          <description>Modified Local SCORAD is the sum of 5 individual indexes; erythema, edema/papulation, oozing/crusts, excoriations and lichenification scored on a 4 point scale, where 0=absent and 3=severe, with a total possible score of 15. Higher scores indicate greater severity.</description>
          <population>All randomized participants who received at least one application of any double-blind study medication with a score at Day 15. One subject in the 0.5% Roflumilast group was missing Day 15 data.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="0.354"/>
                    <measurement group_id="O2" value="-1.75" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.276</p_value>
            <p_value_desc>Mixed Model Repeated Measures (MMRM) Model: SCORAD change from baseline = treatment + visit + treatment by visit interaction + baseline SCORAD score</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.496</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5542</ci_lower_limit>
            <ci_upper_limit>0.4574</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values</title>
        <description>Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>All randomized participants who received at least one application of any double-blind study medication with a score at Day 15. One subject in the 0.5% Roflumilast group was missing Day 15 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5% Roflumilast Cream</title>
            <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15 in Transepidermal Water Loss (TEWL) Values</title>
          <description>Diffusion of water through the skin is measured using a Tewameter. At each visit, 3 measurements are taken per treatment area (at 3 different areas of the target lesion). The TEWL value at each visit is the average of these measurements.</description>
          <population>All randomized participants who received at least one application of any double-blind study medication with a score at Day 15. One subject in the 0.5% Roflumilast group was missing Day 15 data.</population>
          <units>g/m^2/hr</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.60" spread="2.467"/>
                    <measurement group_id="O2" value="-12.69" spread="2.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.095</p_value>
            <p_value_desc>MMRM model: TEWL change from baseline = treatment + visit + treatment by visit interaction + baseline TEWL score</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.454</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.9134</ci_lower_limit>
            <ci_upper_limit>1.0835</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 15 in Participants’ Assessment of Pruritus</title>
        <description>Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>All randomized participants who received at least one application of any double-blind study medication with a score at Day 15. One subject in the 0.5% Roflumilast group was missing Day 15 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5% Roflumilast Cream</title>
            <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Cream</title>
            <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 15 in Participants’ Assessment of Pruritus</title>
          <description>Severity of pruritus is assessed by the participants and recorded on a numeric scale ranging from 0 to 10, where 0 indicates the absence of the symptoms and 10 indicates the most severe symptoms.</description>
          <population>All randomized participants who received at least one application of any double-blind study medication with a score at Day 15. One subject in the 0.5% Roflumilast group was missing Day 15 data.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="0.426"/>
                    <measurement group_id="O2" value="-1.50" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>MMRM model: Assessment of Pruritus change from baseline = treatment + visit + treatment by visit interaction + baseline Assessment of Pruritus score</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.596</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7656</ci_lower_limit>
            <ci_upper_limit>-0.3492</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time informed consent is signed through 7 days after the last dose of study drug (up to Day 22)</time_frame>
      <desc>The population consisted of all randomized participants. At each visit, investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment</desc>
      <group_list>
        <group group_id="E1">
          <title>0.5% Roflumilast Cream</title>
          <description>Roflumilast 0.5%, cream, topically, twice daily for up to 15 days.</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Cream</title>
          <description>Roflumilast formulation vehicle, cream, topically, twice daily for up to 15 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>AstraZeneca Clinical Study Information Center</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>1-877-240-9479</phone>
      <email>information.center@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

